iBio Announces MUC16 as its Latest Immune-Oncology Target

– The company has raised antibodies against a specific region of MUC16 –

– Possibly offers a differentiated and powerful tool in the fight against cancer –

BRYAN, Texas, Feb. 16, 2023 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Disclosure of known MUC16 as the target of its latest immuno-oncology program.

MUC16 is a well-known cancer target that is commonly overexpressed in several types of solid tumors, including ovarian, lung, and pancreatic cancer. In particular, MUC16 is a large extracellular protein that is expressed on more than 80% of ovarian tumors. Tumor cells can evade immune attack by shedding or glycosylating MUC16, making it difficult for traditional antibody therapies to target and destroy the cancer cells effectively.

Using its patented epitope guidance AI platform, iBio’s innovative approach to this challenge allows its new monoclonal antibodies (mAbs) to bind to a specific region of MUC16 that is not secreted or glycosylated, bypassing both tumor evasion mechanisms and potentially a powerful tool in the fight against cancer.

“Targeting a very specific, pathophysiologically relevant region of MUC16 is a testament to the versatility of our AI technology as it successfully demonstrates that it can be applied to a wide range of targets,” said iBio’s Interim Chief Executive Officer and Chief Scientific Officer, Martin Brenner: “This achievement adds to the growing list of target classes for which we have generated differentiated antibodies using our patented epitope steering technology.”

Read  The Real Heroes of ‘Quantumania’ Hit Back at The Haters

The addition of the MUC16 program expands iBio’s immuno-oncology portfolio, complementing its Treg depletion programs IBIO-101 and CCR8, as well as its program targeting the tumor-specific EGFRvIII protein.

About iBio, Inc.

iBio is developing next-generation biopharmaceuticals using computational biology and 3D modeling of subdominant and conformational epitopes that are expected to enable the discovery of new antibody treatments for hard-to-hit cancers and other diseases. iBio’s mission is to reduce drug failures, shorten drug development timelines, and open new frontiers to the most promising targets. Visit for more information.


Certain statements in this press release are “forward-looking statements” within the meaning of the federal securities laws. Words such as “may”, “could”, “will”, “should”, “believe”, “expect”, “anticipate”, “estimate”, “continue”, “predict”, “forecast”, “forecast” “Plan,” “intend,” or similar expressions or statements of intentions, beliefs, or current expectations are forward-looking statements. These forward-looking statements are based on current estimates and assumptions and include statements regarding the guarantee of broad coverage of the Company’s epitope-targeting antibody detection engine and the engine that gives iBio a competitive advantage. Although the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on such forward-looking statements, which are based on information available to us as of the date of this press release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict and which could cause actual results to differ materially from current expectations and assumptions that differ from the results expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to continue its growth strategy; its ability to obtain regulatory approvals for the commercialization of its product candidates or to meet ongoing regulatory requirements; regulatory restrictions related to its ability to promote or commercialize its product candidates for certain indications; market acceptance of its product candidates and successful product development, marketing or sale; its ability to maintain its license agreements; the continued maintenance and growth of its patent portfolio; its ability to obtain or maintain capital or grants required to fund its research and development activities and whether the Company will incur unanticipated expenses or liabilities or other market factors; successful compliance with governmental regulations applicable to its manufacturing facility; Competition; its ability to retain its key employees or maintain its listing on the NYSE American; and the other factors discussed in the company’s filings with the SEC, including the company’s annual report on Form 10-K for the year ended June 30, 2022 and the company’s subsequent filings with the SEC on Forms 10- Q and 8-K. The information in this press release is provided only as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statements in this press release, whether as a result of new information, future events or otherwise, except as required by law.

Read  Now is the best time to switch to eSIM...


Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
[email protected]


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button